Summary
Introduction
Based on reports from double-blind cross-over studies, involving abrupt cessation of both nonselective and cardio-selective padrenoreceptor blockers, the padrenoreceptor-blocker-withdrawal syndrome is now generally accepted in both angina (Wilson, Watson & Peel, 1969; Miher, Olson & Amsterdam, 1975; Frick & Luurila, 1976) and in hypertension (O'Brien & McKinnon, 1972; Lederballe Pedersen, 1976; Lederballe Pedersen, Mikkelsen, Nielsen & Christensen, 1979) .
In hypertension, the syndrome comprises tachycardia, angina pectoris, sweating, tremor and general malaise, described as resembling thyrotoxicosis (O'Brien & McKinnon, 1972) , and, as in angina, the time of onset of symptoms has varied greatly, from 1 to several days. As the withdrawal symptoms were described as resembling thyrotoxicosis we decided to investigate the effect of abrupt cessation of propranolol on serum concentrations of thyroxine (T,) and tri-iodothyronine (T3 in patients with uncomplicated essential hypertension.
Material
Details from the present study have been published (Kristensen, Steiness & Weeke, 1978) . Five euthyroid patients, two males and three females, with essential hypertension in WHO stage I, were studied (age range 28-57 years). Informed consent was obtained from each patient.
417s
All received propranolol in the following doses: 160 mg/day (two patients), 240 mg/day (one), 400 mg/day (one) and 480 mg/day (one). The treatment period before the study ranged from 2 to 18 months on an unchanged maintenance dose. Four patients also received hydrochlormethiazide 50 (mg/day) and one patient was given 200 mg of hydrallazine daily. Serum thyroid hormones were normal before propranolol treatment. None of the patients had goitres, and none of the females used oral contraceptives.
Methods
The patients were admitted to hospital during the experimental period. On the day of admission, they were given their usual medication. The next day propranolol was discontinued, and additional therapy was maintained, except for hydrallazine, which also ceased.
Blood pressure and heart rate were recorded four times a day in the supine position after at least 20 min at rest. The supine position was chosen in order to minimize the effect of noradrenaline, known to increase in the erect position.
A circadian variation, and a superimposed variation with a cycle length of about 30 min in serum free T, and free T, has recently been demonstrated (Weeke & Gundersen, 1976) . In order to minimize the influence of these two regular rhythms, each patient had blood samples taken at exactly the same time each day, and six consecutive samples at 5 min intervals were drawn daily through a catheter inserted in an antecubital vein. Total serum propranolol was determined in the same samples. The first samples were drawn 3-6 h after the last propranolol dose. Blood pressure was measured after 20 rnin at rest by using a sphygmomanometer with randomized zero (Wright & Dore, 1970) . Heart rate was counted over 1 min and tachycardia was defined as lying resting heart rate 2 95 beatdmin.
Serum was prepared within 2 h and stored at -18OC until analysed. Thyroid hormones were determined by radioimmunoassay techniques (Weeke & Orskov, 1978) , and total serum propranolol by chromatographic methods (Walle, 1974) . All analyses were performed in duplicate, and all samples from one patient were analysed in the same assay. Statistical significance was assessed by analysis of variance and Student's ttest for paired observations.
Unless severe withdrawal symptoms developed, the patients were followed until heart rate had reached a maximum. Recordings of blood pressure and heart rate, and evaluation of the clinical symptoms, were performed by the same observer throughout, and at a time when he had no knowledge of the hormonal values.
Results
Within 2-6 days after withdrawal of propranolol, four of the five patients developed tachycardia, sweating or tremor. One patient (no. 5, see Fig. 1 ) developed severe symptoms and ischaemic ECG changes on the fourth day, and it was necessary to resume propranolol (80 mg orally) in her case. Within 2 h after resumption her symptoms were greatly diminished and the ECG changes disappeared. No patients developed anginal attacks. Two patients developed only milder symptoms, which disappeared spontaneously the next day (nos. 1 and 4). One patient (no. 3) had to leave hospital 4 days after withdrawal. At that time she had developed tachycardia only. The last patient (no. 2) showed no signs of withdrawal symptoms.
A mean relative increase in serum free T, of 51 k SD 9% with a range from 22 to 74% was found in the four patients on the day of onset of their symptoms. The absolute values are shown in Fig. 1 together with an indication of the relative severity of the symptoms observed. The three patients who developed sweating and/or tremor showed the highest value of free T,, whereas the patient who did not develop any symptoms had an unchanged value of free T, on the day with maximal recorded heart rate. The last patient, who developed tachycardia only, had a T, value similar to the patient with no symptoms, but she had shown a large relative increase (68%). A significant positive correlation between total serum propranolol the last day the drug was given, and the maximal relative increase in serum free T, was found (r = 0.91, 2 P = 0.03).
Heart rate increased significantly from the first day of withdrawal of propranolol and was maximal the day the symptoms were observed. The mean increase in these patients was 35 k SEM 5 beats/min and 25 beatshin in the patient without symptoms. A positive correlation between heart rate and serum free T, was found in only one patient (no. 1, r = 0.95, 2 P = 0.001). Serum free T, and total thyroid hormones did not change significantly during the study, neither did blood pressure in any of the patients.
Serum propranolol fell to zero on the second day of withdrawal in all patients, although admission values had ranged from 56 to 281 ng/ml. In only one patient (no. 4), heart rate was maximal that day.
Discussion
Within 2-6 days after the abrupt withdrawal of propranolol in patients with uncomplicated essential hypertension, four of five patients developed tachycardia, sweating or tremor. In one patient also ischaemic ECG changes were recorded. Lederballe Pedersen, 1976) . The higher incidence found in this study might well be explained by the close observation of the patients during the experiment. In the present study an increase in serum free T, was observed in patients with the withdrawal syndrome. In two patients T, increased gradually, and in the remaining two abruptly, but in all cases, the increase was maximal and coincidental with the appearence of symptoms, despite a variation in time of onset from 2 to 6 days. Furthermore, the increase in T, was linear and positively correlated to total serum propranolol, and in accordance with this, the patient who developed the most severe symptoms had a serum propranolol of 219 ng/ml and showed the highest increase in T, (74%), whereas the patient who did not develop any symptoms had a rather low serum propranolol concentration (56 ng/ml) and showed no changes in T, on the day of maximal recorded heart rate.
Recent studies have reported on a propranololinduced inhibition of the monodeiodination of T, to Kristensen & Weeke, 1977) , and the observed increase in serum T, after abrupt withdrawal of propranolol might be explained as a rebound increase in T, production, caused by the sudden removal of a monodeiodonation inhibitor (propranolol).
The mechanism underlying the / 3-adrenoreceptor-blocker-withdrawal syndrome is unknown, and one may speculate whether the observed increase in T, production could produce this syndrome. Several groups have suggested a catecholamine-mediated pathogenetic mechanism, but recent studies have failed to demonstrate any association between serum concentrations or urinary excretion of these amines and the syndrome (Patano 8c Lee, 1976; Lederballe Pedersen et al., 1979) , which seems compatible with the observation of an unaltered resting lying blood pressure within the first 2-7 days after withdrawal of badrenoreceptor blockers, even in patients with the syndrome (Lederbde Pedersen et al., 1979) .
In this context it might be relevant to compare the withdrawal syndrome with that for clonidine. The clinical symptoms are much alike with regard to tachycardia, sweating and headaches, but the clonidine-withdrawal syndrome is associated with a rebound increase in blood pressure and serum concentrations of catecholamines (Hunyor, Hansson, Harrison & Hoobler, 1973 Goldberg, Raftery & Wilkinson, 1977) . Moreover, the clonidine-withdrawal syndrome most often begins within 18-24 h after the last clonidine dose, whereas the padrenoreceptor-blocker-withdrawal syndrome has shown a great variation in time of onset of symptoms, from 1 to several days, which was also found in this study. This variation seems not to be explained by a variation in elimination rate of propranolol, as propranolol could not be detected in serum on the second day of withdrawal in any of our patients. This is in agreement with previous studies, which have shown that plasma and tissue elimination rates of propranolol are identical (Faulkner, Hopkins & Boerth, 1973 ; Romagnoli & Keats, 1976) . In this connection it should be emphasized that the pharmacokinetics of the active 4-hydroxypropranolol are similar to those of propranolol.
In this study an association between the increase in free T, and the appearance of withdrawal symptoms was found, despite a variation in time of onset of symptoms from 2 to 6 days, which seems to indicate that T, is involved in the pathogenesis of the padrenoreceptor-blocker-withdrawal syndrome. This assumption could explain the symptoms observed, the unchanged resting blood pressure and serum concentrations of catecholamines, and also the reported transient increased padrenoreceptor sensitivity (Boudoulas, Lewis, Kates & Dalamangas, 1977) after abrupt cessation of propranolol. This latter effect of the thyroid hormones has been suggested in thyrotoxic patients (Christensen, 1973) .
At present, there are no methods available by means of which patients at special risk of suffering the withdrawal syndrome can be selected. Because of the high risk for fatal withdrawal symptoms in angina, cessation of padrenoreceptor-blockers should, whenever necessary, be done gradually, irrespective of the disease for which the drug is being given.
